FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Ragan Paula		 2. Issuer Name and Ticker or Trading Symbol

X4 Pharmaceuticals, Inc [ XFOR ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
President and CEO
(Last)          (First)          (Middle)

C/O X4 PHARMACEUTICALS, INC., 955 MASSACHUSETTS AVENUE, 4TH FLOOR		 3. Date of Earliest Transaction (MM/DD/YYYY)

5/4/2020
(Street)

CAMBRIGE, MA 02139
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 5/4/2020  S(1)  2400 D$8.92 (2)230094 (3)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
(1) The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
(2) The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $8.87 to $8.99, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
(3) Of the shares of common stock reported, 55,928 shares represent unvested restricted stock units.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Ragan Paula
C/O X4 PHARMACEUTICALS, INC.
955 MASSACHUSETTS AVENUE, 4TH FLOOR
CAMBRIGE, MA 02139

President and CEO
Signatures
/s/ Derek M. Meisner, attorney-in-fact5/5/2020
**Signature of Reporting PersonDate
X4 Pharmaceuticals (PK) (USOTC:XFOWW)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more X4 Pharmaceuticals (PK) Charts.
X4 Pharmaceuticals (PK) (USOTC:XFOWW)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more X4 Pharmaceuticals (PK) Charts.